checkAd
    Startseite > Aktien > Marinus Pharmaceuticals > Nachrichten
    Marinus Pharmaceuticals Aktie
    1,3100
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 12:24:02 Tradegate
    1,2900
     
    EUR
    2.400 STK
    Geldkurs 14:42:48
    1,3400
     
    EUR
    2.300 STK
    Briefkurs 14:42:48
    ISIN: US56854Q2003 · WKN: A2QEUC · SYM: 61Y · USA

    Neueste Nachrichten

    Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
    15.04.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    05.04.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
    27.03.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    05.03.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
    21.02.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
    20.02.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    16.02.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    04.01.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update
    04.01.24 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    07.12.23 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
    20.11.23 · Business Wire (engl.) · Marinus Pharmaceuticals
    Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
    14.11.23 · Business Wire (engl.) · Marinus Pharmaceuticals